These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 35514955)

  • 21. Evolving Real-World Effectiveness of Monoclonal Antibodies for Treatment of COVID-19 : A Cohort Study.
    Kip KE; McCreary EK; Collins K; Minnier TE; Snyder GM; Garrard W; McKibben JC; Yealy DM; Seymour CW; Huang DT; Bariola JR; Schmidhofer M; Wadas RJ; Angus DC; Kip PL; Marroquin OC
    Ann Intern Med; 2023 Apr; 176(4):496-504. PubMed ID: 37011399
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Influence of treatment with neutralizing monoclonal antibodies on the SARS-CoV-2 nasopharyngeal load and quasispecies.
    Vellas C; Del Bello A; Debard A; Steinmeyer Z; Tribaudeau L; Ranger N; Jeanne N; Martin-Blondel G; Delobel P; Kamar N; Izopet J
    Clin Microbiol Infect; 2022 Jan; 28(1):139.e5-139.e8. PubMed ID: 34537363
    [TBL] [Abstract][Full Text] [Related]  

  • 23. PK/PD modeling links accelerated resolution of COVID-19-related clinical symptoms to SARS-CoV-2 viral load reduction in patients following treatment with Bamlanivimab alone or Bamlanivimab and Etesevimab together.
    Ernest CS; Chien JY; Patel DR; Chigutsa E
    CPT Pharmacometrics Syst Pharmacol; 2022 Jun; 11(6):721-730. PubMed ID: 35289125
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A Comparison of SARS-COV-2 Neutralizing Antibody Therapies in High-Risk Patients with Mild to Moderate COVID-19 Disease at a Single Academic Hospital.
    Farcy DA; Dalley MT; Miro G; Swalley P; Sherman D; Nash J; Jodoin K; Cubeddu LX; Zitek T; Goldszer R
    J Emerg Med; 2022 Jan; 62(1):83-91. PubMed ID: 34489146
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Virologic Efficacy of Casirivimab and Imdevimab COVID-19 Antibody Combination in Outpatients With SARS-CoV-2 Infection: A Phase 2 Dose-Ranging Randomized Clinical Trial.
    Portal-Celhay C; Forleo-Neto E; Eagan W; Musser BJ; Davis JD; Turner KC; Norton T; Hooper AT; Hamilton JD; Pan C; Mahmood A; Baum A; Kyratsous CA; Kim Y; Parrino J; Kampman W; Roque-Guerrero L; Stoici R; Fatakia A; Soo Y; Geba GP; Kowal B; DiCioccio AT; Stahl N; Lipsich L; Braunstein N; Herman GA; Yancopoulos GD; Weinreich DM;
    JAMA Netw Open; 2022 Aug; 5(8):e2225411. PubMed ID: 35969402
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dual Monoclonal Antibodies on Sars-Cov-2 Alpha and Delta Variants: Clinical and Virological Efficacy.
    Ferré VM; Peiffer-Smadja N; Kramer L; Coppée R; Kante A; Debarge M; Choquet C; Saint Joannis T; Bouzid D; Messika J; Le Grand J; Thy M; Kernéis S; Descamps D; Visseaux B; Ghosn J
    Microbiol Spectr; 2022 Oct; 10(5):e0215222. PubMed ID: 36125289
    [TBL] [Abstract][Full Text] [Related]  

  • 27. SARS-CoV-2 neutralizing antibody therapies: an early retrospective cohort study of 26 hospitalized patients treated with bamlanivimab or casirivimab/imdevimab.
    Heller M; Henrici C; Büttner J; Leube S; Treske I; Pospischil P; Doll M; Schanz I; Hallier A; Herrmann E; Schmidt M; Sarrazin C
    Int J Infect Dis; 2023 Apr; 129():260-265. PubMed ID: 36690138
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19.
    Dougan M; Nirula A; Azizad M; Mocherla B; Gottlieb RL; Chen P; Hebert C; Perry R; Boscia J; Heller B; Morris J; Crystal C; Igbinadolor A; Huhn G; Cardona J; Shawa I; Kumar P; Adams AC; Van Naarden J; Custer KL; Durante M; Oakley G; Schade AE; Holzer TR; Ebert PJ; Higgs RE; Kallewaard NL; Sabo J; Patel DR; Dabora MC; Klekotka P; Shen L; Skovronsky DM;
    N Engl J Med; 2021 Oct; 385(15):1382-1392. PubMed ID: 34260849
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Early administration of SARS-CoV-2 monoclonal antibody reduces the risk of mortality in hematologic malignancy and hematopoietic cell transplant patients with COVID-19.
    Jabr R; Khatri A; Anderson AD; Garcia LC; Viotti JB; Natori Y; Raja M; Camargo JF; Morris MI
    Transpl Infect Dis; 2023 Feb; 25(1):e14006. PubMed ID: 36704987
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of bamlanivimab alone or in combination with etesevimab on subsequent hospitalization and mortality in outpatients with COVID-19: a systematic review and meta-analysis.
    Tai YL; Lee MD; Chi H; Chiu NC; Lei WT; Weng SL; Liu LY; Chen CC; Huang SY; Huang YN; Lin CY
    PeerJ; 2023; 11():e15344. PubMed ID: 37180576
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of Bamlanivimab as Monotherapy or in Combination with Etesevimab or Sotrovimab on Persistently High Viral Load in Patients with Mild-to-Moderate COVID-19: A Randomized, Phase 2 BLAZE-4 Trial.
    Nichols RM; Macpherson L; Patel DR; Yeh WW; Peppercorn A
    Infect Dis Ther; 2024 Feb; 13(2):401-411. PubMed ID: 38291279
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Real-World Clinical Outcomes of Bamlanivimab and Casirivimab-Imdevimab Among High-Risk Patients With Mild to Moderate Coronavirus Disease 2019.
    Ganesh R; Philpot LM; Bierle DM; Anderson RJ; Arndt LL; Arndt RF; Culbertson TL; Destro Borgen MJ; Hanson SN; Kennedy BD; Kottke BB; Larsen JJ; Ramar P; Rosedahl JK; Seville MT; Speicher LL; Tulledge-Scheitel SM; Wilker CG; Razonable RR
    J Infect Dis; 2021 Oct; 224(8):1278-1286. PubMed ID: 34279629
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of Casirivimab/Imdevimab Monoclonal Antibody Treatment among Vaccinated Patients Infected by SARS-CoV-2 Delta Variant.
    Cicchitto G; Cardillo L; de Martinis C; Sabatini P; Marchitiello R; Abate G; Rovetti A; Cavallera A; Apuzzo C; Ferrigno F; Fusco G
    Viruses; 2022 Mar; 14(3):. PubMed ID: 35337057
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact analysis of SARS-CoV-2 vaccination in patients treated with monoclonal antibodies: A monocentric experience.
    Perrotta N; Angelo Fiorito L; Leanza C; Di Bari S; Casini G; Gentile R; Vescovo R; Piciocchi A; Ajassa C; Iaiani G; Maria Proli E; Russo G
    Int Immunopharmacol; 2024 Dec; 142(Pt A):113101. PubMed ID: 39265354
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comprehensive Treatment of Hematological Patients with SARS-CoV-2 Infection Including Anti-SARS-CoV-2 Monoclonal Antibodies: A Single-Center Experience Case Series.
    Boeckel GR; Hölscher SD; Bürger C; Jacob T; Krekeler C; Shumilov E; Reicherts C; Bleckmann A; Lenz G; Vollenberg R; Tepasse PR
    Curr Oncol; 2022 Mar; 29(4):2312-2325. PubMed ID: 35448162
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antibody and cellular therapies for treatment of covid-19: a living systematic review and network meta-analysis.
    Siemieniuk RA; Bartoszko JJ; Díaz Martinez JP; Kum E; Qasim A; Zeraatkar D; Izcovich A; Mangala S; Ge L; Han MA; Agoritsas T; Arnold D; Ávila C; Chu DK; Couban R; Cusano E; Darzi AJ; Devji T; Foroutan F; Ghadimi M; Khamis A; Lamontagne F; Loeb M; Miroshnychenko A; Motaghi S; Murthy S; Mustafa RA; Rada G; Rochwerg B; Switzer C; Vandvik PO; Vernooij RW; Wang Y; Yao L; Guyatt GH; Brignardello-Petersen R
    BMJ; 2021 Sep; 374():n2231. PubMed ID: 34556486
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Neutralizing Monoclonal Antibody Use and COVID-19 Infection Outcomes.
    Ambrose N; Amin A; Anderson B; Barrera-Oro J; Bertagnolli M; Campion F; Chow D; Danan R; D'Arinzo L; Drews A; Erlandson K; Fitzgerald K; Garcia M; Gaspar FW; Gong C; Hanna G; Jones S; Lopansri B; Musser J; O'Horo J; Piantadosi S; Pritt B; Razonable RR; Roberts S; Sandmeyer S; Stein D; Vahidy F; Webb B; Yttri J
    JAMA Netw Open; 2023 Apr; 6(4):e239694. PubMed ID: 37093599
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Assessing the safety and pharmacokinetics of casirivimab and imdevimab (CAS+IMD) in a cohort of pregnant outpatients with COVID-19: results from an adaptive, multicentre, randomised, double-blind, phase 1/2/3 study.
    Norton TD; Thakur M; Ganguly S; Ali S; Chao J; Waldron A; Xiao J; Patel Y; Turner KC; Davis JD; Irvin SC; Pan C; Atmodjo-Watkins D; Hooper AT; Hamilton JD; Subramaniam D; Bocchini JA; Kowal B; DiCioccio AT; Bhore R; Geba GP; Cox E; Braunstein N; Dakin P; Herman GA
    BMJ Open; 2024 Oct; 14(10):e087431. PubMed ID: 39384241
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Successful early use of anti-SARS-CoV-2 monoclonal neutralizing antibodies in SARS-CoV-2 infected hematological patients - A Czech multicenter experience.
    Weinbergerová B; Demel I; Víšek B; Válka J; Čerňan M; Jindra P; Novák J; Stejskal L; Kovácsová F; Kabut T; Szotkowski T; Hájek R; Žák P; Cetkovský P; Král Z; Mayer J
    Hematol Oncol; 2022 Apr; 40(2):280-286. PubMed ID: 35120267
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An update of antispike severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) monoclonal antibodies.
    Chatterjee S; Choudhury S; Das D
    Indian J Pharmacol; 2022; 54(1):51-57. PubMed ID: 35343208
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.